The effects of a combination therapy of clonidine with dextromethorphan and/or amantadine on opium withdrawal syndrome compared with the single therapy of clonidine

Study of the effects of a combination therapy of clonidine with dextromethorphan and/or amantadine on opium withdrawal syndrome compared with the single therapy of clonidine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201207196972N2

Enrollment

120

Registered

2012-08-30

Start date

2011-06-07

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mental and behavioural disorders due to use of opioids. Mental and behavioural disorders due to use of opioids

Interventions

Intervention 1: The first group will receive clonidine tablet 0.4-1.2 mg per day in three subdivided doses according to the patient's tolerance, clonazepam tablet one mg per eight hours and acetaminop

Treatment - Drugs

The first group will receive clonidine tablet 0.4-1.2 mg per day in three subdivided doses according to the patient's tolerance, clonazepam tablet one mg per eight hours and acetaminophen tablet 500 m

The second group will receive clonidine tablet 0.4-1.2 mg per day in three subdivided doses according to the patient's tolerance, clonazepam tablet one mg per eight hours,acetaminophen tablet 500 mg e

The third group will receive clonidine tablet 0.4-1.2 mg per day in three subdivided doses according to the patient's tolerance, clonazepam tablet one mg per eight hours, acetaminophen tablet 500 mg e

The fourth group will receive clonidine tablet 0.4-1.2 mg per day in three subdivided doses according to the patient's tolerance, clonazepam tablet one mg per eight hours, amantadine capsule 100 mg ev

Eligibility

Sex/Gender

Male

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : Male sex; Aging from 20 to 40 years;Positive morphine test; Substance abuse diagnosis according to the DSM-IV-TR criteria. Exclusion criteria:The hepatic and renal diseases will evaluate according to the Creatinine and ALT measurements and if the subjects have levels higher than 1.2 mg/dl and 40 IU, respectively, will exclude; Also all patients will evaluate by clinical interview and the psychotic patientswill exclude.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Relieving the opioid withdrawal symptoms. Timepoint: Admission day, and 24, 48, and 72 hours later. Method of measurement: Clinical Opiate Withdrawal Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Shahrokh Amiri

Tabriz University of Medical Sciences

Amirish@tbzmed.ac.ir+98 41 1380 4490

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026